Transform treatment for immune-mediated diseases, empower people to reimagine their lives.
About Alumis
We are advancing a late-stage portfolio of next-generation targeted therapies to optimize patient outcomes across a wide range of immune-mediated diseases.
PIPELINE
Our precision approach builds on integrated scientific insights – powered by our proprietary data analytics platform – to drive smarter therapeutic development.
science
We foster a culture where teams elevate, challenge, and nurture each other, living our values while driving our mission forward.
careers
November 12, 2026 Alumis Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates
October 9, 2026 Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures
September 4, 2026 Alumis to Participate in Upcoming September Investor Conferences
More News
